Business Context and Reporting Period
This Form 8-K is filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) for the reporting period of February 16, 2018. The company is an emerging growth company incorporated in Nevada. The filing reports the final closing of a Securities Purchase Agreement entered into on January 19, 2018, with Emerald Health Sciences Inc. and an accredited investor.
Key Financial Metrics
- Capital Raised: Aggregate gross proceeds of $1,750,000.
- Equity Issued: 17,500,000 shares of common stock (15,000,000 to Emerald; 2,500,000 to an accredited investor).
- Warrants Issued: Warrants to purchase 23,440,000 shares total (20,040,000 to Emerald; 3,400,000 to an accredited investor).
- Warrant Terms: Exercise price of $0.10 per share with a five-year term.
- Use of Proceeds: General corporate purposes, including working capital.
- Other Metrics: The filing does not provide specific data on revenue, profit, cash flow, margins, debt, or liquidity ratios.
Material Changes
The primary material change is the completion of the equity financing transaction on February 16, 2018. This resulted in an immediate increase in outstanding common stock and the creation of new warrant obligations. The transaction was conducted under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, exempting it from registration.
Outlook, Risks, and Management Commentary
Management intends to utilize the $1.75 million in proceeds for general corporate purposes and working capital. The filing includes a press release (Exhibit 99.1) announcing the closing. No specific forward-looking guidance, risk factors, or contingencies beyond the standard disclosure of the unregistered sale of equity are detailed in this specific 8-K text.
Investor Verification Checklist
- Verify the total number of outstanding shares post-closing to assess dilution impact.
- Confirm the current cash balance and burn rate to evaluate the sufficiency of the $1.75 million working capital injection.
- Review the full text of the Securities Purchase Agreement for any restrictive covenants or liquidation preferences not detailed in the summary.
- Check subsequent filings for the actual utilization of proceeds versus the stated "general corporate purposes."
- Monitor the exercise activity of the 23,440,000 warrants issued at the $0.10 strike price.